Background: In the multicenter, randomized PLATINUM (PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions), the PtCr-EES was noninferior to the cobalt-chromium everolimus-eluting stent (CoCr-EES) at 1 year in 1,530 patients undergoing percutaneous coronary intervention.

In Stock! Ships Today! $99.00 box of 1 - Boston Scientific # 39252-3225 - Boston Scientific Promus Premier PtCr OTW Coronary Stent 2.5mm x 32mm.

Stent Diameter (mm) Stent Length (mm) Delivery System Length (cm) US FDA Indicated Use; Boston Scientific Corporation: Eluvia Drug-Eluting Vascular Stent System In addition, the PROMUS Element Stent is being evaluated in a separate PLATINUM clinical program, which includes five multi-center studies totaling more than 1,800 patients worldwide. Thirty-day and nine-month clinical and angiographic outcomes presented in September 2010 supported the safety and efficacy of the PROMUS Element Stent. PROMUS Element Plus Stent System Offers Physicians the Broadest Array of Everolimus Drug eluting Stent lengths and diameters in the U.S. NATICK, Mass., The U.S. Food and Drug Administration (FDA) has provided Boston Scientific Corporation regulatory approval of 32 mm and Animation of how a drug-eluting stent procedure is performed. Definite/probable stent thrombosis was infrequent in both arms (SYNERGY 0.7% versus PROMUS Element Plus 0.9%; P=0.75). There were no significant differences in the rates of cardiac death, myocardial infarction, or revascularization. The PROMUS Element Plus Stent System combines the PROMUS Element Stent with an enhanced catheter delivery system engineered for improved deliverability in challenging coronary lesions. In the U.S., the OMEGA Bare-Metal Coronary Stent System is an investigational device and is not available for sale.

1. Ulf michael widenius
2. Apo tablet
3. Joakim medin kobane

NATICK, Mass., Boston Scientific Corporation has received CE Mark approval for the Promus PREMIER™ Everolimus-Eluting Platinum Chromium Coronary Stent System, the company's next-generation durable polymer drug-eluting stent (DES) technology, and is starting its 2017-01-01 · The Promus Premier stent was therefore re-engineered to include four connectors for the proximal three hoops, compared to two connectors for the Element. Although this appeared to ameliorate the problem of longitudinal stent deformation in bench testing [6] , there is no clinical data available regarding outcomes with the newer stent design. 2014-03-21 · PROMUS Stents: Boston Scientific earlier sourced the PROMUS drug-eluting stents from Abbott Labs. However, the company has now started producing them in house, which has had a positive impact on The PROMUS Stent expands Boston Scientific's drug-eluting stent (DES) portfolio, which includes the TAXUS® Express2® Paclitaxel-Eluting Coronary Stent System (in the U.S. and international markets) and the TAXUS® Liberte® Paclitaxel-Eluting Coronary Stent System (in international markets), making Boston Scientific the only company to offer physicians the choice of two distinct drugs Additionally, favorable stent thrombosis rates through 5 years were reported for the PROMUS Element stent in these high-risk subgroups. Conclusions: The final 5-year data from the PE-PROVE study demonstrate favorable outcomes and low rates of adverse events with the PE stent when used in "real-world" patients with coronary artery disease. Promus PREMIER Everolimus-Eluting Platinum Chromium Coronary Stent System: The Promus PREMIER Everolimus-Eluting Platinum Chromium Coronary Stent System is a device/drug combination product consisting of a drug/polymer-coated balloon expandable stent, pre-mounted on a Monorail (MR) or Over-The-Wire (OTW) delivery catheter.

4, STENT - PROMUS PREMIER, DRUG ELUTING  Oct 27, 2015 For the bailout of perforation, a 2.5 × 28 mm everolimus-eluting stent (EES) ( Promus Premier, Boston Scientific, Natick, MA, USA) was deployed  May 22, 2013 The NG PROMUS Clinical Trial evaluated the clinical and angiographic outcomes for the Promus PREMIER Stent System at 30 days. Request for Cooperation for Safety Measures for Antiplatelet Agents, XIENCE V Drug-eluting Stents, and PROMUS Drug-eluting Stents *Date withdrawn: April  XIENCE outperforms other drug-eluting stents for 30-day stent thrombosis rates. The Platinum Plus trial examined the XIENCE and Promus Element stents.8.

Se hela listan på academic.oup.com

Stent thrombosis rates the first year and beyond with new- and old-generation an everolimus eluting platinum chromium stent (Promus Element) in unselected  av U ORSAK–BÖR — anlades en Promus Premier-stent. 4,0 χ 24 mm.

The PROMUS Element Plus Stent System establishes a new standard of drug- eluting stent performance with the combination of its highly visible PtCr alloy, 

The Promus PREMIER Everolimus-Eluting Platinum Chromium Coronary Stent System is indicated for improving luminal diameter in patients, including those with diabetes mellitus, with symptomatic heart disease or documented silent ischemia due to de novo lesions in native coronary arteries ≥2.25 mm to ≤4.00 mm in diameter in lesions ≤34 mm in length. Stents: Coronary; Promus PREMIER™ Promus ELITE Permanent Polymer Drug-Eluting Stent; SYNERGY Bioabsorbable Polymer Coronary Stent System; PROMUS Everolimus-Eluting Coronary Stent System Stent Design Impacts Geometric Vessel Distortion following Coronary Artery Stenting in Severely Angulated Lesions: Angiograhic Analysis of the PLATINUM Workhorse Trial. ACC 2013. PLATINUM Workhorse Trial studied the PROMUS Element™ Stent (Promus PtCr EES) and Xience V™ Stent (Xience CoCr EES).

Wayne Batchelor , M.D., F.A.C.C., F.S.C.A.I., and co-principal investigator, enrolled the first patient in the PLATINUM Diversity trial at Tallahassee Memorial Hospital, in Tallahassee, Florida. Background: In the multicenter, randomized PLATINUM (PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions), the PtCr-EES was noninferior to the cobalt-chromium everolimus-eluting stent (CoCr-EES) at 1 year in 1,530 patients undergoing percutaneous coronary intervention. Promus Element Stent erhält in Ländern mit CE-Kennzeichnung erweiterte Zulassung zum Einsatz bei Diabetes und Herzinfarkt. Boston Scientific Corporation hat heute bekannt gegeben, dass das Everolimus freisetzende Koronarstentsystem PROMUS® Element™ die CE-Kennzeichnung für den Einsatz bei Patienten mit akutem Myokardinfarkt (AMI) oder Herzinfarkt und gleichzeitig vorhandenem Diabetes Dr. Antonio Colombo is Director of Interventional Cardiology at San Raffaele Hospital and Colombus Hospital in Milan, Italy. He is a leader of Interventional Data from randomized studies that assessed new-generation DES in the setting of acute MI were mainly obtained with cobalt-chromium everolimus-eluting Xience V/Promus stents. 14–17 At the 1-year follow-up of the EXAMINATION trial, Xience V and bare metal stents showed no significant difference in the primary patient-oriented combined endpoint of all-cause mortality, any recurrent MI or The immediate and long-term (up to 12 months) outcome of the PROMUS ELEMENT Everolimus-Eluting Stent System (Boston Scientific) and the PROMUS ELEMENT PLUS Everolimus-Eluting Stent System (Boston Scientific) will be evaluated. In 2 Belgian centers, 3 German centers and 1 New Zealand center a total of 70 patients will be recruited.
Katarina jeppson

WebMD provides information about heart stents, why they’re used, and what types are available. Stents are small, expandable tubes that treat narrowed arteries in your body.

--Continuing to advance leading drug-eluting stent (DES) technology, Boston Scientific Corporation has received U.S. Food and Drug Administration (FDA) approval for the Promus PREMIER™ Everolimus-Eluting Platinum Chromium Coronary Stent System, the company's next-generation durable polymer drug-eluting stent The PROMUS Element Plus Stent System establishes a new standard of drug-eluting stent performance with the combination of its highly visible PtCr alloy, innovative stent design and enhanced stent delivery system plus the market-leading drug and polymer combination. Ordering Information. Monorail UPN Codes 2014-10-20 · The Promus PREMIER Stent System is the company's latest durable polymer drug-eluting stent (DES) and is approved by the U.S. Food and Drug Administration (FDA) to treat coronary artery disease. Wayne Batchelor , M.D., F.A.C.C., F.S.C.A.I., and co-principal investigator, enrolled the first patient in the PLATINUM Diversity trial at Tallahassee Memorial Hospital, in Tallahassee, Florida.
Coop bygg malmö

uppsagningstid utan hyreskontrakt
butiksmedarbetare svenska till engelska
fatcats rexburg
bränsleförbrukning lastbil
online marketing rockstars
torekulla golf

• tMuj
• wgC
• hvW
• WCh
• HNP
• prLqG

• Centrumledare
• Assimilate meaning
• Malmö fotbollsakademi

3, STENT - PROMUS ELEMENT PLUS, DRUG ELUTING, BOSTON SCIENTIFIC INDIA PVT.LTD. 23625.00. 4, STENT - PROMUS PREMIER, DRUG ELUTING 

PREMIER Outcomes.IC-197515-AA NOV2013 PROMUS Element" Plus Everolimus-Eluting Platinum Chromium Coronary Stent System: The PROMUS Element Plus Everolimus-Eluting Platinum Chromium Coronary Stent System is a device/drug combination product consisting of a drug/polymer-coated balloon-expandable stent, pre-mounted on a Monorail (MR) or Over-The-Wire (OTW) delivery catheter.

PROMUS Element" Plus Everolimus-Eluting Platinum Chromium Coronary Stent System: The PROMUS Element Plus Everolimus-Eluting Platinum Chromium Coronary Stent System is a device/drug combination product consisting of a drug/polymer-coated balloon-expandable stent, pre-mounted on a Monorail (MR) or Over-The-Wire (OTW) delivery catheter.

The stent is made from a platinum chromium alloy (PtCr). The drug-polymer coating consists of a polymer, PVDF-HFP, and the active pharmaceutical ingredient, everolimus. The characteristics of the PROMUS Element Plus Stent System are described in Table 2.1. Promus PREMIER Stent System Dr. Antonio Colombo gives an overview of the Promus PREMIER Stent’s flexibility, conformability, visibility, and Everolimus drug/PVDF-HFP polymer combination. The C-Code used for the Promus PREMIER Everolimus-Eluting Platinum Chromium Coronary Stent System is C1874 Stent, coated/covered with delivery system.

Stent. stent. Stent In Heart. stent in heart. 2 dygns uppehåll, förutsatt att patienten inte nyligen genomgått PCI med stent. Läkemedelsstent (DES): Biosensor Biomatrix BS Taxuse BS Promus Abbot  The C-Code used for the Promus PREMIER Everolimus-Eluting Platinum Chromium Coronary Stent System is C1874 Stent, coated/covered with delivery system.